Engineered Enzymes Powering The Future Of mRNA Therapeutics

The rapid expansion of mRNA therapeutics requires advanced manufacturing solutions that legacy enzymes often fail to provide. This poster introduces Prima RNApols™, engineered RNA polymerases developed via an ultra-high-throughput enzyme evolution platform. These proprietary enzymes are designed to overcome the limitations of standard T7 RNA polymerase by optimizing yield, integrity, and purity.

A primary focus of this research is the ExTend Cap AU variant, which is specifically engineered for self-amplifying mRNA (saRNA). Data shows it achieves higher capping efficiency with lower cap analog concentrations while dramatically reducing double-stranded RNA (dsRNA) levels. Furthermore, it produces significantly fewer abortive transcripts, leading to higher purity for complex DNA templates. These innovations provide a scalable, cost-effective path for the next generation of vaccines and therapeutics.